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Aims Human immunodeficiency virus infection (HIV) has been associated with cardiac dysfunction that, if present, can
negatively affect morbidity and mortality of HIV-infected patients. Unfortunately, many of the studies on this topic
were performed before the highly active antiretroviral therapy (HAART) was established. Thus, we performed a




Medline, Cochrane Library, and Biomed Central were systematically screened for studies reporting on systolic and/or
diastolic dysfunctions in HIV pauci-symptomatic patients. Baseline treatment and cardiac imaging data were appraised
and pooled with random effect methods computing summary. At pooled analysis, including a total of 2242 patients
from 11 studies, an overall average incidence of traditional cardiovascular risk factors was observed, while a low rate
of previous coronary artery disease was reported. Incidence of systolic and diastolic left ventricular dysfunction was
8.33% (95% CI: 2.20–14.25) and 43.38% (95% CI: 31.73–55.03), respectively. Diastolic dysfunction was graded as
first [31.85% (95% CI: 24.85–43.73)], second [8.53% (95% CI: 2.12–14.93)], and third degree [3.02% (95% CI:
1.78–4.27)]. At multivariate analysis, a high sensitivity C-reactive protein level .5 mg/L, active tobacco smoking
and previous history of myocardial infarction were predictors of left ventricular systolic dysfunction [odd ratio
1.70 (95% CI: 1.03–2.77); 1.57 (95% CI: 1.03–2.34); and 15.90 (95% CI: 1.94–329.00), respectively]. Hypertension
(OR ¼ 2.30; 95% CI: 1.20–4.50) and older age (OR ¼ 2.50 per 10 years increase; 95% CI: 1.70–3.60) were predic-
tors of left ventricular diastolic dysfunction (Figure 3).
Conclusions Systolic and diastolic dysfunction represent a common finding in pauci symptomatic HIV-infected patients, regardless
to HAART.
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Introduction
Several studies have reported a strong association between human
immunodeficiency virus (HIV) infection and cardiac abnormalities,
which are closely associated with high morbidity and mortality.1,2
Human immunodeficiency virus itself, as well as the autoimmune
response, and the high cardiovascular risk profile of HIV-positive
patients are the main mechanisms leading to cardiac dysfunction.2
With regard to coronary heart disease, recent data3,4 have sug-
gested antiretroviral therapy as a predictor of atherosclerotic
plaque progression possibly resulting in consequent ischaemic
events.
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The occurrence of cardiomyopathy secondary to HIV infection
is less common, but it has been reported in up to 10% of these
patients.5 –9 In most of the cases, cardiac dysfunction is transient
and asymptomatic; however, progression towards overt left ven-
tricular (LV) failure has been previously described.9 Unfortunately,
many of the studies on this topic were performed before highly
active antiretroviral therapy (HAART) became the mainstay of
treatment for HIV-positive patients. This combination of drugs
resulted in a significant reduction in the incidence of myocarditis
and opportunistic infections leading to a drop in Human immuno-
deficiency virus-associated cardiomyopathy, thus contributing to a
greater life expectancy.10
However, the real incidence of clinical or subclinical cardiac ab-
normalities remains uncertain in spite of contemporary cardiac
imaging techniques capable of detecting even mild degrees of sys-
tolic and diastolic LV dysfunction. Therefore, a meta-analysis was
performed in order to critically appraise the real incidence of
cardiac dysfunction in HIV-infected pauci-symptomatic population
receiving HAART.
Methods
The present research was elaborated according to current guidelines,
including the recent Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) amendment to the Quality of Reporting
of Meta-analyses (QUOROM) statement, and recommendations from
The Cochrane Collaboration and Meta-analysis Of Observational
Studies in Epidemiology (MOOSE).11 –14 No language restrictions
were applied.
Search strategy and study selection
Pertinent articles were searched in Medline, Cochrane Library, Biomed
Central in keeping with established methods15 with MESH strategy and
with terms related to HIV patients presenting LV dysfunction: [heart
failure OR cardiomyopathy OR ((systolic OR diastolic) dysfunction)]
AND [HIV OR aids OR (human AND immunodeficiency AND
virus)]. Studies appraising HIV patients cohort alone or both HIV-
and non-HIV-positive patients were also included.
Three independent reviewers (G.B.-Z, F.D.A., and E.C.) first
screened retrieved citations at the title and/or abstract level, with
divergences resolved after consensus. If potentially pertinent, they
were appraised as complete reports according to the following explicit
selection criteria. Studies were included if (i) investigating systolic or
diastolic LV function in HIV patients using a specific cardiac imaging
technique [at least one in each study between echocardiography or
single photon emission computed tomography (SPECT)] (ii) with
clearly description and properly assessment of echocardiography/
SPECT data according to current guidelines;16,17 (iii) with .5% of
patients treated with HAART (defined as the use of three or more
antiretroviral drugs in combination). Exclusion criteria were (i) non-
human setting, (ii) duplicate reporting (in which case the manuscript
reporting the largest sample of HIV-positive patients was selected),
or (iii) unclear or low prevalence of patients treated with HAART.
Data extraction
Three unblinded independent reviewers (G.B.-Z, F.DA, and E.C.)
abstracted the following data on pre-specified forms: authors,
journal, year of publication, location of the study group, baseline fea-
tures, type and timing of antiretroviral therapy, and NYHA class.
Endpoints of interest were rates of systolic or diastolic dysfunction
and their clinical or instrumental predictors.
For each study the definition of systolic dysfunction was defined as
an ejection fraction (EF) ,55% (i) as measured by echocardiography
(ii) or as measured by SPECT.
Diastolic dysfunction was defined according to a multiparametric
approach (including pulse and tissue Doppler parameters) and
graded as mild, moderate, or severe (1, 2, or 3), according to the
American Society of Echocardiography guidelines.16
Multivariate predictors were appraised if derived from studies with
a sample size larger than 100 patients.
Internal validity and quality appraisal
Unblinded independent reviewers (G.B.-Z., F.D.A., and E.C.) evaluated
the overall quality of included studies on pre-specified forms. Modify-
ing the MOOSE items to take into account the specific features of
included studies,14 we separately abstracted and appraised study
design, setting, data source, as well as risk of analytical, selection, adju-
dication, detection, and attrition bias (expressed as low, moderate, or
high risk of bias, as well as incomplete reporting leading to inability to
ascertain the underlying risk of bias).
Data analysis and synthesis
Both for continuous and categorical variables, statistical pooling was
performed according to a random-effect model with generic inverse-
variance weighting, computing risk estimates with 95% confidence
intervals, using RevMan 5 (The Cochrane Collaboration, The Nordic
Cochrane Centre, and Copenhagen, Denmark). Standard hypothesis
testing was set at the two-tailed 0.05 level.
Results
The systematic literature search yielded 356 citations that were
first screened and appraised at the abstract level; 17 articles
were then selected, among which 6 were excluded, because in-
cluding HIV-positive patients not receiving HAART, treated with
a single antiretroviral drug or because ,75% of included patients
were treated with HAART18– 23 (Figure 1). Therefore, 11 studies
were finally included in our meta-analysis; in 9 of them echocardi-
ography was the imaging technique used for the evaluation of
systolic and diastolic function,24– 32 while SPECT was used in
others.33,34
A total of 2242 patients were included, with a median age of 42
years (95% CI: 39–45) showing at pooled analysis an overall
average incidence of traditional cardiovascular risk factors, with
a low rate of previous coronary artery disease [2.40% (95% CI:
1.32–6.11)] (Table 1).
Human immunodeficiency virus syndrome features are reported
in Table 2. Cardiac imaging evaluation was performed at a median
time of 8.1 (6.3, 10.0; 95% CI) years after HIV-infection diagnosis.
Most of the patients were treated with HAART [98.45% (98.14–
98.75; 95% CI)] and showed a mild to moderate reduction in
CD4 + cell count per mm3 [median 489.33 (356.28, 622.38; 95%
CI); Nadir 199.09 (165.81, 232.37; 95% CI)]. Nucleoside reverse-
transcriptase inhibitors [75.30% (95% CI: 59.70–90.90)] were the
most widely used drugs, followed by non-nucleoside reverse-
transcriptase inhibitors [40.43% (95% CI: 28.78–52.08)] and by pro-
tease inhibitors [25.42% (95% CI: 10.58–40.26)]. The median overall
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duration of HAART exposure was 56.6 months (31.8–81.4; 95% CI).
At the time of cardiac imaging all patients were asymptomatic
(NYHA I) without clinical overt signs of heart failure.
At the pooled analysis, the occurrence of systolic and diastolic
LV dysfunction was 8.33% (95% CI: 2.20–14.25) and 43.38%
(95% CI: 31.73–55.03), respectively (Table 3, Supplementary ma-
terial online, Figure SA1). Very similar results were obtained after
the exclusion of studies which used SPECT to assess ventricular
function [LV systolic dysfunction 10.12% (95% CI: 3.10–17.14)].
When reported, diastolic dysfunction was graded as first
[31.85% (95% CI: 24.85–43.73)], second [8.53% (95% CI: 2.12–
14.93)], and third degree [3.02% (95% CI: 1.78–4.27)] (Supple-
mentary material online, Figure SB2).
At multivariate analysis, a high sensitivity C-reactive protein
(sharp) level .5 mg/L, active tobacco smoking and previous
history of myocardial infarction were predictors of LV systolic dys-
function [odd ratio ¼ 1.70 (95% CI: 1.03–2.77); 1.57 (95% CI:
1.03–2.34); and 15.90 (95% CI: 1.94–329.00), respectively]
(Figure 2).
Hypertension (OR ¼ 2.30; 95% CI: 1.20–4.50) and older age
(OR ¼ 2.50 per 10 years increase; 95% CI: 1.70–3.60) were pre-
dictors of LV diastolic dysfunction (Figure 3).
The methodological assessment (Supplementary material online,
Tables SA1 and SB2) showed an overall good quality of the selected
studies, most of them being prospective, one-third of them multi-
center, without high risk of analysed bias (Supplementary material
online, Figure SC3). The vast majority of the included studies was
performed in Europe or North America.
Discussion
The present systematic review and meta-analysis summarizes the
available evidence regarding the incidence of cardiac dysfunction
in HIV-positive pauci-symptomatic patients. Several studies, per-
formed before the current HAART era, have identified cardiac ab-
normalities in HIV patients. In particular, the incidence of LV
systolic dysfunction ranged from 10 to 40% depending on the
progression of the disease, on the type of definition used for ‘sys-
tolic impairment’ and on the presence of a concomitant drug
abuse;35– 37 however, clinically symptomatic cardiomyopathy has
been reported in up to 10% of HIV-positive patients only.5,6 In
two studies a very high incidence of LV diastolic dysfunction has
also been reported.38,39
Figure 1 Review’s profile.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 HIV syndrome’s features
Pooled analysis
(95% C.I.)a
Time from diagnosis of HIV infection
(years)
8.12 (6.26–9.99)
Median CD4 + cell count per mm3 489.33 (356.28–622.38)
Nadir of CD4 + cell count per mm3 199.09 (165.81–232.37)
Patients with undetectable copies
of HIV-RNA in blood
74.43 (63.71–85.15)
Patients treated with highly active
antiretroviral therapy
98.45 (98.14–98.75)
Duration of HAART exposure (months) 56.62 (31.83–81.40)
Patients exposed to protease inhibitors
(previous or current)
25.42 (10.58–40.26)








aValues are median or percentages.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline features
Pooled analysis (95% CI)a
Age (years) 42.02 (39.19–44.85)
Hypertension 21.09 (15.02–27.16)
Patients with hypertriglyceridaemia 15.79 (7.02–24.56)
Diabetes mellitus 4.81 (2.24–7.37)
Current smoker 23.38 (9.44–37.33)
Previous coronary artery disease 2.40 (1.32–6.11)
NYHA I (I– II)
aValues are median or percentages
E. Cerrato et al.1434






Different potentially contributing factors cause HIV-related car-
diomyopathy. Viral, toxoplasmatic or fungal opportunistic infections
and nutritional deficiencies (e.g. selenium) may play an important
role.40,41 It has also been hypothesized a direct invasion of the HIV
genome in the cardiomyocytes or an autoimmune response trig-
gered by the restoration of the immune competence during anti-
retroviral therapy.42– 44 All the mechanisms mentioned above are
related to severe immunodeficiency combined with a high viral
load. As reported by Twagirumukiza et al.45 in a multicenter,
observational, prospective, cohort study of 416 not-HAART-treated
patients, duration of HIV-1 infection, CD4 count, and HIV-1 viral
load were associated with the development of cardiomyopathy
both at univariate and multivariate analysis.
The introduction of HAART represented a turning point also for
the cardiac involvement of HIV patients, with a nearly 30% reduction
in HIV-associated cardiomyopathy.10 However, our meta-analysis
shows that both systolic and/or diastolic dysfunction persist
despite a fully active antiretroviral treatment (leading to a mild or
moderate reduction in CD4 cell count) and despite the suppression
of viral replication below the detection limit in three out of four
patients. The duration of viral suppression and the threshold level
to be reached in order to achieve a reduced risk of HIV-associated
disorders are currently not known. Several factors may probably
play a role in the development of the disease: for example, an
impact of antiretroviral drugs has not been well defined. The influ-
ence of antiretroviral drugs on cardiovascular system is still a
matter of debate and a fully-accurate single-drug effect analysis
remains challenging. Anyway, at multivariate adjustment, HAART
drugs did not significantly relate either to systolic or diastolic
dysfunction.
The impact of cardiac dysfunctions on prognosis has not been
well analysed. In a pre-HAART study of 70 HIV asymptomatic
patients,46 LV systolic dysfunction (defined as EF ,45% and frac-
tional shortening ,28%) was reported in 11% of them. Most of
the abnormalities were transient and not consistently associated
with a clinical progression of the disease. Conversely, a persistently
low LV EF was associated with a high mortality rate within the first
year of the follow-up. Therefore, further follow-up data are neces-
sary to confirm these findings even in the HAART therapy era and
additional studies are needed to evaluate the impact of these dys-
functions on survival and quality of life to better define if these
patients require a closer follow-up and to test the potential
benefit of drugs commonly used for heart failure treatment (e.g.
ACE inhibitors, beta-blockers, and mineral corticoid receptor
antagonists).
In addition to imaging parameters, also elevated levels of hsCPR
were independent predictors of systolic dysfunction. In previous
studies, high sensitivity C-reactive protein levels have been
shown to be elevated in patients with HIV compared with
healthy subjects47 and increased high sensitivity C-reactive
protein levels were also associated with a higher relative risk of
acute myocardial infarction.48,49 The relationship between high
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Details regarding left ventricular function
assessment











Definition of diastolic dysfunction n ¼ 7
Spectral Doppler mitral and pulmonary venous inflow
velocity patterns and Doppler tissue imaging of the
lateral mitral annulus. Using the average of septal and
lateral early diastolic velocities (Ea), the E/Ea ratio was
computed. Three cardiac cycles were measured and
averaged for all Doppler measurements
7 (100)
Definition of systolic dysfunction n ¼ 11
Left ventricular (LV) dysfunction was defined as an
ejection fraction ,50%
8 (73)
Left ventricular (LV) dysfunction was defined as an
ejection fraction ,55%
1 (9)
LVEF was measured using a multiple
electrocardiogram-gated equilibrium study in which
the gamma camera was positioned in a left anterior
oblique 301 view, with a caudal tilt of 51–101, and
adjusted for optimal separation of the ventricles
2 (18)
Figure 3 Multivariate predictors of diastolic dysfunction
(reported as OR; 95% CI).
Figure 2 Multivariate predictors of systolic dysfunction
(reported as OR; 95% CI).
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sensitivity C-reactive protein levels and the risk of cardiac dysfunc-
tion in HIV patients has also been previously described highlighting
the role of inflammation, partly triggered by HIV virions and their
harmful effect on cardiomyocytes, partly by the local release of
cytokines.50 Our findings could reflect the presence or the conse-
quence of a myocarditic process in the immunodeficient setting of
a HIV-positive population.51,52 Thus, some studies support the role
of serologic testing and of C-reactive protein as a marker of per-
sistent viral infection and development of dilated cardiomyop-
athy.53,54 Cardiac magnetic resonance imaging could be helpful in
identifying and characterizing myocardial abnormalities, explaining
in which proportion cardiac dysfunctions arise from HIV infection
itself. Anyway, the clinical impact of C-reactive protein elevation
remains to be defined because it may reflect both the status of
the disease, both an epiphenomenon of HIV infection, even if
the study from which was derived (Mondy et al.32) enrolled only
patient receiving routine outpatient care.
Our work shares several important limitations. First, we
appraised infrequent events, with all the limits of reporting uncom-
mon outcomes.55 Secondly, no specific data about the influence of
different associations of antiretroviral drugs were available, making
a pooled analysis unfeasible. Thirdly, it was not possible to analyse
data about baseline treatment and compliance and, as a conse-
quence, to address their role and influence in controlling cardio-
vascular risk factors and inflammation level. Also, data regarding
illicit drugs used were not consistently reported in the included
studies as well as data about concomitant infections (e.g. myocar-
ditis), therefore their impact on LV dysfunction was impossible to
gauge. However, it should be taken into account that both illicit
drug abuse and infections have become infrequent in the current
HAART era.39 Finally, as in all studies based on cardiac imaging,
intra- and inter-observer variability may have limited the accuracy
of LV function estimation and the reliability of our analysis.
In conclusion, the occurrence of systolic and/or diastolic dys-
function in HIV-positive patients receiving HAART is a common,
possibly underecognized, finding, regardless to HAART.
Conflict of interest: none declared.
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